Skip to content
Research/Immune Modulation/Delgocitinib

Delgocitinib

Delgocitinib is a Janus kinase (JAK) inhibitor primarily used for its immunomodulatory effects, particularly in treating inflammatory skin conditions like atopic dermatitis. By inhibiting JAK pathways, it reduces inflammation and immune response, which is crucial for managing chronic inflammatory conditions that can impact longevity and overall health.

Intelligence Profile

Safety Profile

Safety Profile of Delgocitinib

Delgocitinib is generally used in a cream formulation for treating various dermatological conditions, including atopic dermatitis and chronic hand eczema. The safety profile described in the available studies is as follows:

Known Side Effects:

  1. Skin Irritation: Some patients may experience irritation where the cream is applied.
  2. Itching and Redness: Common reactions can include itching (pruritus) and redness at the site of application.
  3. Burning Sensation: A transient burning sensation has been reported, which typically resolves on continued use.

Contraindications:

The current data do not provide explicit contraindications for delgocitinib. However, as with any topical medication, it should not be used by individuals with known hypersensitivity to its components.

Drug Interactions:

Based on the evidence, there are no specific studies detailing interactions between delgocitinib and other medications. This area requires further research for conclusive information.

Populations to Avoid Use:

  1. Pregnant or Nursing Women: The safety of delgocitinib in pregnant or breastfeeding women has not been established.
  2. Children: While a systematic review included pediatric subjects, no conclusive safety data specific to children were highlighted.
  3. Patients with Severe Skin Conditions Beyond Study Scope: Those with skin conditions outside the ones studied, such as severe psoriasis, should use the cream under close medical supervision.

Additional Considerations:

  • Chronic Hand Eczema Studies: Evidence from real-world and phase 2 trials suggests a favorable safety profile for chronic hand eczema, but further real-world data may help solidify understanding.
  • UV-light Sensitivity: A phase 1 study evaluated allergic reactions related to UV exposure, indicating a need for caution regarding sunlight exposure after application.

In summary, while the existing data suggests a favorable safety profile for delgocitinib, the evidence is still evolving, especially concerning specific interactions and use in vulnerable populations. Patients should consult healthcare providers for personalized advice.

Disclaimer: This summary is for informational purposes and should not be used for diagnosing or treating health problems. Please consult a healthcare professional for personal medical advice.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.